Mizuho Securities Reiterates Buy Following Ventas' (VTR) 35% YTD Stock Increase PT to $84
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Ventas Reports 2016 Second Quarter Results
July 29, 2016 6:53 AM EDTContinued Strong Track Record of Earnings Growth Enhanced Companys Credit Profile Through Excellent Capital Markets Execution Announced $1.5 Billion Acquisition of Wexford Life Science and Medical Real Estate
CHICAGO--(BUSINESS WIRE)-- Ventas, Inc. (NYSE: VTR) (Ventas or the Company) today announced strong earnings on a healthy balance sheet for the second quarter of 2016, driven by excellent performance from the Companys high-quality healthcare and senior living properties and accretive acquisitions:
Income from continuing operations per diluted common share for... More